Giblari subcutaneous injection 189mg, manufactured by Alnylam Japan, contains givosiran sodium. Givosiran is an RNA interference therapeutic indicated for the treatment of acute hepatic porphyria (AHP). It works by reducing the levels of aminolevulinate synthase 1 (ALAS1) mRNA. It is supplied as a 189mg/1mL/1 bottle injectable drug (YJ code: 3999461A1023).
Giblari subcutaneous injection 189mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).